Donors for SARS-CoV-2 convalescent plasma for a controlled clinical trial : donor characteristics, content and time course of SARS-CoV-2 neutralizing antibodies
Corman, Victor M.
Transfusion Medicine and Hemotherapy ; 48 (2021), 3. - S. 137-146. - ISSN 1660-3796. - eISSN 1660-3818
Link to original publicationhttps://dx.doi.org/10.1159/000515610
InstitutionsInstitut für Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH (IKT)
UKU. Institut für Transfusionsmedizin
Document versionpublished version (publisher's PDF)
Background: Convalescent plasma is one of the treatment options for COVID-19 which is currently being investigated in many clinical trials. Understanding of donor and product characteristics is important for optimization of convalescent plasma. Methods: Patients who had recovered from COVID-19 were recruited as donors for COVID-19 convalescent plasma (CCP) for a randomized clinical trial of CCP for treatment of severe COVID-19 (CAPSID Trial). Titers of neutralizing antibodies were measured by a plaque-reduction neutralization test (PRNT). Correlation of antibody titers with host factors and evolution of neutralizing antibody titers over time in repeat donors were analysed. Results: A series of 144 donors (41% females, 59% males; median age 40 years) underwent 319 plasmapheresis procedures providing a median collection volume of 850 mL and a mean number of 2.7 therapeutic units per plasmapheresis. The majority of donors had a mild or moderate course of COVID-19. The titers of neutralizing antibodies varied greatly between CCP donors (from <1:20 to >1:640). Donor factors (gender, age, ABO type, body weight) did not correlate significantly with the titer of neutralizing antibodies. We observed a significant positive correlation of neutralization titers with the number of reported COVID-19 symptoms and with the time from SARS-CoV-2 diagnosis to plasmapheresis. Neutralizing antibody levels were stable or increased over time in 58% of repeat CCP donors. Mean titers of neutralizing antibodies of first donation and last donation of repeat CCP donors did not differ significantly (1:86 at first compared to 1:87 at the last donation). There was a significant correlation of neutralizing antibodies measured by PRNT and anti-SARS-CoV-2 IgG and IgA antibodies which were measured by ELISA. CCP donations with an anti-SARS-CoV-2 IgG antibody content above the 25th percentile were substantially enriched for CCP donations with higher neutralizing antibody levels. Conclusion: We demonstrate the feasibility of collection of a large number of CCP products under a harmonized protocol for a randomized clinical trial. Titers of neutralizing antibodies were stable or increased over time in a subgroup of repeat donors. A history of higher number of COVID-19 symptoms and higher levels of anti-SARS-CoV-2 IgG and IgA antibodies in immunoassays can preselect donations with higher neutralizing capacity.
Subject headings[GND]: SARS-CoV-2 | COVID-19 | Blutspende | Antikörper
[MeSH]: SARS-CoV-2 | COVID-19 | Antibodies, Neutralizing | Blood donors | COVID-19; Blood
[Free subject headings]: Neutralizing antibody | COVID-19 | Convalescent plasma | Plasma donors
[DDC subject group]: DDC 610 / Medicine & health
LicenseCC BY-NC 4.0 International
MetadataShow full item record
DOI & citation
Please use this identifier to cite or link to this item: http://dx.doi.org/10.18725/OPARU-50401